Loading company…
Turn Biotechnologies develops epigenetic therapies for age-related cellular dysfunction.
Founded in 2018, Turn Biotechnologies develops mRNA-based epigenetic therapies intended to address age-related diseases and cellular dysfunction. Its ERA™ technology is designed to target specific tissues and restore cell vitality. Based in San Francisco, US, the company raised USD 29.13 mn in Series A funding on August 22, 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in